ホーム › 乳がん › マサチューセッツ州 › Boston
Boston、MAにおける乳がんの臨床試験
Bostonとその周辺地域（約30マイル以内）の拠点で、乳がんに関する112件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
被験者募集中第1/2相
- Research Site, Boston
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
被験者募集中第3相
- Tufts Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of PHST001 in Advanced Solid Tumors
被験者募集中第1相
- Dana Farber Cancer Institute, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
被験者募集中第2相
- Dana-Farber Cancer Institute - Oncology Department, Boston
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
被験者募集中第3相
- Dana Farber Cancer Institute, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
被験者募集中
- Dana-Farber Cancer Institute, Boston
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
被験者募集中第2相
- Dana Farber Cancer Institute, Boston
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
被験者募集中第2相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
被験者募集中第1相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Insitute, Boston
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
被験者募集中第1/2相
- Dana-Farber Cancer Institute, Boston
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
被験者募集中第1相
- Massachusetts General Hospital, Boston
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
被験者募集中第1相
- Research Site, Boston
- Research Site, Boston
IKS014 in Advanced Solid Tumors That Express HER2
被験者募集中第1相
- Dana Farber Cancer Institute, Boston
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
被験者募集中第3相
- Massachusetts General Hospital, Boston
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
被験者募集中第3相
- Dana-Farber Cancer Institute-Breast Oncology Center ( Site 0037), Boston
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
被験者募集中第3相
- Dana-Farber Cancer Institute, Boston
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
被験者募集中第3相
- Massachusetts General Hospital Cancer Center ( Site 0091), Boston
- Dana Farber Cancer Institute ( Site 0090), Boston
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
被験者募集中
- Massachusetts General Hospital, Boston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
被験者募集中第1相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
被験者募集中第1相
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
被験者募集中第3相
- Mass General Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
被験者募集中第2相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
被験者募集中第1相
- Massachusetts General Hospital, Boston
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
被験者募集中第3相
- Dana Farber Cancer Institute, Boston
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
被験者募集中第3相
- Massachusetts General Hospital, Boston
- Boston Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- 他1件
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
被験者募集中第1/2相
- Research Site, Boston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
被験者募集中第1相
- Dana Farber Cancer Institute, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
被験者募集中第2相
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Phase 1/1b Study of IAM1363 in HER2 Cancers
被験者募集中第1相
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
被験者募集中第1/2相
- Dana-Farber Cancer Institute, Boston
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
被験者募集中第1相
- Dana-Farber Cancer Institute, Boston
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
被験者募集中第1/2相
- Dana Farber Cancer Institute, Boston
Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
被験者募集中第1相
- Dana-Farber Cancer Institute, Boston
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
被験者募集中第3相
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- Dana-Farber Cancer Institute, Boston
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
被験者募集中第1/2相
- Dana Farber Cancer Institute, Boston
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
被験者募集中第2相
- Dana-Farber Cancer Institute, Boston
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
被験者募集中第2相
- Dana-Farber Cancer Institute, Boston
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
被験者募集中第1相
- Dana-Farber Cancer Institute, Boston
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
被験者募集中第1相
- Dana Farber Cancer Institute, Boston
ATEMPT 2.0: Adjuvant T-DM1 vs TH
被験者募集中第2相
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
Optimizing Surgical Decisions in Young Adults With Breast Cancer
被験者募集中
- Dana-Farber Cancer Institute, Boston
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
被験者募集中第1相
- Massachusetts General Hospital, Boston
Supporting Health Including Endocrine Treatment for Long Duration
被験者募集中
- Dana-Farber Cancer Institute, Boston
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
被験者募集中第2/3相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
被験者募集中第2相
- Dana-Farber Cancer Institute, Boston
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
被験者募集中第3相
- Massachusetts General Hospital Cancer Center, Boston
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
被験者募集中第2相
- Dana-Farber Cancer Institute, Boston
E-Mindfulness Approaches for Living After Breast Cancer
被験者募集中第3相
- Tufts Medical Center, Boston
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
被験者募集中第1相
- Dana-Farber Cancer Institute, Boston
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
被験者募集中健康なボランティア歓迎
- Massachusetts General Hospital, Boston
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
被験者募集中第1相
- Massachusetts General Hospital, Boston
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
被験者募集中第2相
- Dana-Farber Cancer Institute, Boston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
被験者募集中第2相
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
被験者募集中
- Dana Farber Cancer Institute, Boston
Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer
被験者募集中健康なボランティア歓迎
- Massachusetts General Hospital, Boston
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
被験者募集中第1相
- Dana-Farber Cancer Institute, Boston
Screening For BCRL In Targeted Therapy For Breast Cancer
被験者募集中観察研究
- Massachusetts General Hospital, Boston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
被験者募集中観察研究
- Dana-Farber Cancer Institute, Boston
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
被験者募集中第1/2相
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
被験者募集中第2相
- GSK Investigational Site, Boston
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
被験者募集中第3相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
Scalp Cooling in MBC
被験者募集中第2相
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
被験者募集中第3相
- Dana-Farber Cancer Institute, Boston
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
被験者募集中第1/2相
- Dana-Farber Cancer Institute, Boston
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
被験者募集中第1相
- Dana Farber Cancer Institute, Boston
Oncoplastic Surgery Outcomes Database
被験者募集中観察研究
- Tufts Medical Center, Boston
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
被験者募集中第1/2相
- Dana-Farber Cancer Institute ( Site 0050), Boston
Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
被験者募集中観察研究
- Dana-Farber Cancer Institute, Harvard Medical School, Boston
Video Education With Result Dependent dIsclosure
被験者募集中
- Dana Farber Cancer Institute, Boston
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
被験者募集中第3相
- Massachusetts General Hospital Cancer Center, Boston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
被験者募集中第2相
- Massachusetts General Hospital Cancer Center, Boston
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
被験者募集中第2相
- Dana-Farber Cancer Institute, Boston
VS-6766+Abema+Fulv in Met HR+/HER- BC
被験者募集中第1/2相
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institite, Boston
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
被験者募集中第2相
- Dana Farber Cancer Institute, Boston
Remote Monitoring and Symptom Management Digital Application
被験者募集中
- Massachusetts General Hospital, Boston
Exercise in Metastatic Breast Cancer: EMBody
被験者募集中
- Dana-Farber Cancer Institute, Boston
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
被験者募集中第1相
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study
被験者募集中第2相健康なボランティア歓迎
- Dana-Farber Cancer Institute, Boston
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
被験者募集中第2相
- Dana-Farber Cancer Institute, Boston
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
被験者募集中
- Beth Israel Deaconess Medical Center, Boston
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
被験者募集中第1/2相
- Dana-Farber Cancer Institute, Boston
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
被験者募集中第1/2相
- Dana-Farber Cancer Institute, Boston
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
被験者募集中観察研究
- Eastern Cooperative Oncology Group, Boston
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
被験者募集中観察研究
- Eastern Cooperative Oncology Group, Boston
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
被験者募集中観察研究
- Eastern Cooperative Oncology Group, Boston
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
被験者募集中第2相
- Dana Farber Cancer Institute (Data Collection Only), Boston
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
被験者募集中第4相
- Massachussets General Hospital, Boston
Impact of Pectoral Versus Paravertebral Blocks on Pain and Physical Well-Being in Implant-Based Breast Reconstruction
被験者募集中
- Massachusetts General Hospital, Boston
Refining Local-Regional Therapy for IBC
被験者募集中
- Dana Farber Cancer Institute, Boston
Prospective Screening for Breast Cancer-related Lymphedema
被験者募集中観察研究
- Massachusetts General Hospital, Boston
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
被験者募集中健康なボランティア歓迎
- Dana Farber Cancer Institute, Boston
Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer
被験者募集中
- Massachusetts General Hospital, Boston
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
被験者募集中第2相
- Massachusetts General Hospital, Boston
Strength After Breast Cancer
被験者募集中
- MGH Institute of Health Professions, Boston
The Cancer of the Pancreas Screening-5 CAPS5)Study
被験者募集中第3相
- Dana Farber Cancer Center, Harvard University, Boston
The COMPASSION Study
被験者募集中
- Dana-Farber Cancer Institute, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
被験者募集中第1/2相
- Dana Farber Cancer Institute, Boston
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
被験者募集中第1相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
TRUDI: TDXD+Durva in HER2+/Low IBC
被験者募集中第2相
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Comprehensive Outcomes for After Cancer Health
被験者募集中健康なボランティア歓迎
- Dana Farber Cancer Institute, Boston
他の都市における乳がんの試験
- New York City, NY136件の研究
- Houston, TX126件の研究
- Nashville, TN81件の研究
- Los Angeles, CA73件の研究
- Edison, NJ68件の研究
- St. Louis, MO64件の研究
- Queens, NY64件の研究
- Durham, NC64件の研究
- Chicago, IL59件の研究
- Philadelphia, PA56件の研究
- Dallas, TX55件の研究
- Arlington, VA47件の研究
Bostonにおける他の研究
- 非小細胞肺癌90件の研究
- がん（全種類）85件の研究
- 転移性癌63件の研究
- 大腸癌63件の研究
- 肺がん62件の研究
- 卵巣がん61件の研究
- 前立腺がん59件の研究
- うつ病52件の研究
- 子宮内膜がん50件の研究
- 心不全44件の研究
- 急性骨髄性白血病44件の研究
- 膵臓がん43件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。